Low-dose intravenous pamidronate reduces fractures in childhood osteoporosis

J Pediatr Endocrinol Metab. 2003 Jul-Aug;16(6):887-92. doi: 10.1515/jpem.2003.16.6.887.

Abstract

Despite the proven efficacy of low-dose pamidronate in adults with osteoporosis, the efficacy of the low-dose regimen in children has not been studied. Pamidronate (1 mg/kg) was administered intravenously once every 3 months to 11 children with osteoporosis. Treatment was associated with reduced fracture rates and increased areal (BMD) and volumetric (BMAD) bone mineral density measured by dual energy X-ray absorptiometry (DXA). The mean annualized percent gain was 20.1 +/- 16.9 (4.7 to 59.1, n = 9) for spinal BMD and 15.1 +/- 18.1 (-11.0 to 40.2, n = 9) for spinal BMAD. Common adverse effects including fever, muscle aches, nausea and fatigue were self-limited and generally occurred only after the first infusion. Clinically significant hypocalcemia did not occur. Low-dose pamidronate appears promising in the treatment of childhood osteoporosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Absorptiometry, Photon
  • Adolescent
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / adverse effects
  • Anti-Inflammatory Agents / therapeutic use*
  • Bone Density / drug effects
  • Calcium / blood
  • Child
  • Diphosphonates / administration & dosage
  • Diphosphonates / adverse effects
  • Diphosphonates / therapeutic use*
  • Female
  • Fractures, Bone / epidemiology
  • Fractures, Bone / prevention & control*
  • Growth / drug effects
  • Hormones / blood
  • Humans
  • Injections, Intravenous
  • Male
  • Osteoporosis / complications*
  • Osteoporosis / drug therapy*
  • Pamidronate
  • Weight Gain / drug effects

Substances

  • Anti-Inflammatory Agents
  • Diphosphonates
  • Hormones
  • Pamidronate
  • Calcium